Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORUVAIL vs CODOXY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, leading to decreased inflammation, pain, and fever.
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia. Oxycodone is combined with aspirin to provide additive analgesic effects.
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Acute painful shoulder (bursitis/tendinitis),Acute gouty arthritis,Juvenile idiopathic arthritis (off-label),Dysmenorrhea (off-label)
Management of moderate to moderately severe pain where the use of an opioid analgesic is appropriate
100 to 200 mg orally twice daily
1-2 capsules orally every 4-6 hours as needed for pain, not to exceed 8 capsules per day. Each capsule contains 5 mg hydrocodone bitartrate and 325 mg acetaminophen.
5-9 hours (terminal elimination half-life); in elderly or renal impairment, may extend up to 20 hours; clinical context: dosing adjustments recommended in renal impairment.
Terminal half-life is 3.5 hours in patients with normal renal function; extends to 5-8 hours in moderate renal impairment.
Primarily hepatic via CYP2C9; undergoes extensive first-pass metabolism. Major metabolites include hydroxylated and carboxylated derivatives.
Oxycodone is metabolized by CYP3A4 and CYP2D6. N-demethylation to noroxycodone (via CYP3A4) is the primary metabolic pathway. CYP2D6-mediated O-demethylation to oxymorphone is a minor pathway but produces a more potent metabolite.
Primarily renal excretion of metabolites (60-80%) with less than 1% unchanged drug; biliary/fecal excretion accounts for 20-40%.
Renal excretion of unchanged drug accounts for approximately 70% of elimination; biliary/fecal excretion accounts for 30%.
99% bound primarily to albumin.
Approximately 92% bound to albumin.
0.1-0.2 L/kg; indicates low tissue distribution consistent with extensive protein binding.
2.4 L/kg; indicates extensive tissue distribution.
Oral: 80-100% (immediate-release); topical: approximately 5% systemic absorption.
Oral: 60-70% due to first-pass metabolism.
GFR 30-89 m L/min: no adjustment; GFR <30 m L/min: contraindicated
For GFR 30-50 m L/min: administer every 8 hours. For GFR 10-29 m L/min: administer every 12 hours. For GFR <10 m L/min: use not recommended.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% and extend interval to every 8 hours. Child-Pugh Class C: contraindicated.
Not recommended for use in pediatric patients
For children ≥2 years: 0.1-0.2 mg/kg hydrocodone component every 4-6 hours as needed, maximum 6 doses per day. Use weight-based dosing; do not exceed acetaminophen 75 mg/kg/day.
Initiate at lowest effective dose (100 mg/day); monitor renal function and gastrointestinal bleeding risk
Initiate at lowest effective dose (e.g., 1 capsule every 6 hours) due to increased risk of respiratory depression and falls. Titrate cautiously. Maximum 6 capsules per day.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Oruvail is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and interactions with drugs affecting cytochrome P450 isoenzymes.
Cardiovascular thrombotic events; gastrointestinal bleeding, ulceration, and perforation; hypertension; congestive heart failure; renal toxicity; anaphylactoid reactions; serious skin reactions; hematologic toxicity; use with caution in patients with asthma, pre-existing renal impairment, or hepatic impairment.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; severe hypotension; gastrointestinal obstruction; seizures; serotonin syndrome; adrenal insufficiency; and androgen deficiency.
Hypersensitivity to ketoprofen or any component of the formulation; history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery; advanced renal disease; active GI bleeding or ulceration.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; hypersensitivity to oxycodone, aspirin, or any component of the formulation.
Take with food or milk to minimize gastrointestinal irritation. Avoid alcohol as it increases risk of GI bleeding. No significant food-drug interactions; however, high-fat meals may delay absorption but does not affect overall bioavailability.
Avoid alcohol and grapefruit juice. Alcohol potentiates CNS depression. Grapefruit juice may increase codeine metabolism via CYP3A4, leading to variable effects. No significant food restrictions otherwise; take with food if GI upset occurs.
First trimester: Avoid; associated with increased risk of cardiac defects and gastroschisis (OR 1.21-3.08). Second trimester: Caution; NSAIDs may cause oligohydramnios. Third trimester: Contraindicated; risk of premature ductus arteriosus closure and persistent pulmonary hypertension.
No human data; animal studies not available. Avoid during pregnancy, especially first trimester, due to potential oxycodone-induced neural tube defects.
Minimal excretion in breast milk (M/P ratio not reported). Use with caution; may cause adverse effects in neonates. Consider alternative analgesics.
Oxycodone is excreted into breast milk; M/P ratio ~3.6:1. Risk of infant sedation and respiratory depression. Contraindicated during breastfeeding.
No dose adjustment recommended but avoid in 3rd trimester. Use lowest effective dose for shortest duration in 1st and 2nd trimesters.
No established dose adjustments; increased clearance in pregnancy may require higher doses for analgesia, but use is contraindicated.
Oruvail (ketoprofen extended-release) is an NSAID with analgesic, anti-inflammatory, and antipyretic effects. Due to its extended-release formulation, it should not be crushed or chewed. Use with caution in patients with renal impairment, history of GI bleeding, or cardiovascular disease. Monitor renal function and blood pressure periodically. It inhibits platelet aggregation similarly to aspirin but is reversible. May mask signs of infection.
CODOXY is a fixed-dose combination of codeine (opioid) and doxylamine (antihistamine). Use lowest effective dose for shortest duration due to opioid dependence and respiratory depression risk. Avoid in children <12 years for post-tonsillectomy pain and in those <18 with respiratory compromise. Monitor for CNS depression, especially with alcohol. Doxylamine adds anticholinergic effects (constipation, dry mouth, urinary retention). Caution in elderly, renal impairment, and breastfeeding.
Take exactly as prescribed; do not crush or chew the capsules.,Take with food or milk to reduce stomach upset.,Avoid alcohol and other NSAIDs (including over-the-counter ibuprofen or naproxen).,Report any signs of GI bleeding (black/tarry stools, vomiting blood), unexplained weight gain, edema, or worsening kidney function (decreased urination).,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Do not use if you have a history of asthma, hives, or allergic reaction to aspirin or NSAIDs.,Inform all healthcare providers that you are taking this medication, especially before surgery.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other sedatives (e.g., benzodiazepines, sleep aids) as they increase risk of severe drowsiness and breathing problems.,Do not use with other products containing codeine or antihistamines (including cough/cold medicines).,Store securely away from children; misuse can cause addiction, overdose, or death.,If you are pregnant, plan to become pregnant, or are breastfeeding, inform your healthcare provider before use.,Common side effects: constipation, dry mouth, nausea. Increase fluid intake and fiber to prevent constipation.,Seek emergency help if you experience slow or shallow breathing, confusion, or fainting.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORUVAIL vs CODOXY, answered by our medical review team.
ORUVAIL is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, leading to decreased inflammation, pain, and fever.. CODOXY is a Antitussive Combination that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia. Oxycodone is combined with aspirin to provide additive analgesic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORUVAIL and CODOXY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORUVAIL is: 100 to 200 mg orally twice daily. The standard adult dose of CODOXY is: 1-2 capsules orally every 4-6 hours as needed for pain, not to exceed 8 capsules per day. Each capsule contains 5 mg hydrocodone bitartrate and 325 mg acetaminophen.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORUVAIL and CODOXY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORUVAIL is classified as Category C. First trimester: Avoid; associated with increased risk of cardiac defects and gastroschisis (OR 1.21-3.08). Second trimester: Caution; NSAIDs may cause oligohydramnios. Third trime. CODOXY is classified as Category C. No human data; animal studies not available. Avoid during pregnancy, especially first trimester, due to potential oxycodone-induced neural tube defects.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.